title: Dalteparin for pregnant women with thrombophilia - authors' reply.
authors.affiliation: Thrombosis Program, Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada; Ottawa Hospital Research Institute, Ottawa, ON K1H8L6, Canada. Electronic address: mrodger@ohri.ca.
authors.forename: Marc A
authors.initials: MA
authors.lastname: Rodger
authors.affiliation: Obstetric Medicine, Robinson Institute, University of Adelaide, Women's and Children's Hospital, Adelaide, SA, Australia.
authors.forename: William M
authors.initials: WM
authors.lastname: Hague
authors.affiliation: Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
authors.forename: John
authors.initials: J
authors.lastname: Kingdom
authors.affiliation: Centre for Clinical Epidemiology, Jewish General Hospital, Montreal, QC, Canada.
authors.forename: Susan R
authors.initials: SR
authors.lastname: Kahn
authors.affiliation: Ottawa Hospital Research Institute, Ottawa, ON K1H8L6, Canada.
authors.forename: Philip S
authors.initials: PS
authors.lastname: Wells
mesh_terms: D017985:Dalteparin / Q000627:therapeutic use*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000517:prevention & control*; D019851:Thrombophilia / Q000150:complications*
chemical_list: D005343:Fibrinolytic Agents; D017985:Dalteparin